Advanced Search

Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2015 August;106(4 Suppl 3) > Minerva Medica 2015 August;106(4 Suppl 3):17-24

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236

Frequency: Bi-Monthly

ISSN 0026-4806

Online ISSN 1827-1669

 

Minerva Medica 2015 August;106(4 Suppl 3):17-24

PNEUMOLAB PROCEEDINGS 

Idiopathic pulmonary fibrosis landscapes: looking glass from pathology to therapy

Stella G. M. 1, Balestro E. 2

1 Laboratory of Biochemistry and Genetics, Pulmonology Unit, Department of Molecular Medicine, University and IRCCS Policlinico, San Matteo di Pavia Foundation, Pavia, Italy;
2 Pulmonology Unit, Respiratory Disease Department, University of Padua, Padua, Italy

Idiopathic pulmonary fibrosis (IPF) is a rare chronic and ultimately fatal disease resulting in an aberrant scarring and thickening of lung tissue. Molecular pathogenetic mechanisms of IPF are still unknown and till now no effective therapy is known to really improve disease’s outcome. A deeper understanding of IPF biology is now mandatory to clarify IPF origin in order to identify actionable targets. Here we discuss and analyze the data presented by a recent paper published by De Pianto et al. on the prestigious respiratory journal Thorax. The work is focused on how gene expression analysis can be applied to stratify IPF cases based on their risk of disease progression. Moreover they tried to match genetic and phenotypic profiles in order to predict therapeutic response and patients’ prognosis.

language: English


FULL TEXT  REPRINTS

top of page